Thomson Snell & Passmore advises ClinIntel Limited on its acquisition by global biopharmaceutical giant.
Our client, Clinintel Limited, based in Crawley, specialises in the provision of clinical randomization and trial supply management services. In recent years it has grown to become one of the leading companies in the sector.
ClinIntel’s acquisition by a US based global biopharmaceutical services organisation will bring a truly global dimension to its capabilities, as its existing expertise will now be augmented by 75 locations in 50 countries around the world.
We advised on all aspects of the deal and worked closely with Chartered Accountants McBrides Corporate Finance, to ensure the smooth running of the transaction.
Commenting on the acquisition, Joanne Gallagher, a partner in Thomson Snell & Passmore’s Corporate & Commercial team who led the TS&P legal team, said:
We are absolutely delighted to have been asked to act for the shareholders of ClinIntel in relation to this sale. This was a complex transaction which drew on a number of different areas of our corporate and commercial teams’ experience. It was essential that we worked closely with McBrides Corporate Finance to provide a seamless professional service and deliver the required result for our clients.
Nigel Kimber, lead advisor and a director at McBrides Corporate Finance who led the shareholders corporate finance team, said:
Working with Joanne and her team at TS&P we completed the deal in just 5 months. For us, this is the conclusion of a really interesting journey that began 4 years ago when McBrides became accountants to ClinIntel and has culminated with us advising them on this latest chapter in their development. It was a complex deal, partly because of the number of shareholders but also because of the interaction of US/UK accounting regulations. We are delighted it has successfully completed to the satisfaction of all parties.